Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TBX-1400
- Development stage
- Phase 1
- Lead developer
- Taiga Biotechnologies
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
TBX-1400 is an investigational stem cell therapy composed of human donor hematopoietic stem and progenitor cells. It was developed by Taiga Biotechnologies for the treatment of severe combined immunodeficiency (SCID), a rare genetic disorder characterized by profound defects in both humoral and cellular immunity. The therapy involves treating blood stem cells with a proprietary protein prior to transplantation, aiming to improve engraftment and accelerate immune system recovery in patients undergoing bone marrow transplant procedures. TBX-1400 has received Orphan Drug Designation from the FDA for this indication[1][2][8].
Beyond the preview
Go deeper on TBX-1400.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TBX-1400.